Literature DB >> 20824010

The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Jens E Meyer1, Carsten Brocks, Hendrik Graefe, Carola Mala, Natalie Thäns, Markus Bürgle, Annette Rempel, Nicole Rotter, Barbara Wollenberg, Stephan Lang.   

Abstract

Entities:  

Year:  2008        PMID： 20824010      PMCID： PMC2930998          DOI： 10.1159/000151736

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  20 in total

1.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 2.  Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.

Authors:  B Muehlenweg; S Sperl; V Magdolen; M Schmitt; N Harbeck
Journal:  Expert Opin Biol Ther       Date:  2001-07       Impact factor: 4.388

Review 3.  Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system.

Authors:  P Carmeliet; D Collen
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

4.  Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.

Authors:  H Nekarda; J R Siewert; M Schmitt; K Ulm
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

5.  Urokinase receptor up-regulation in head and neck squamous cell carcinoma.

Authors:  M Schmidt; G Schler; P Gruensfelder; J Müller; F Hoppe
Journal:  Head Neck       Date:  2000-08       Impact factor: 3.147

Review 6.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

7.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

8.  Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.

Authors:  Suna Ertongur; Stephan Lang; Brigitte Mack; Katja Wosikowski; Bernd Muehlenweg; Olivier Gires
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

9.  Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.

Authors:  S Nozaki; Y Endo; S Kawashiri; K Nakagawa; E Yamamoto; Y Yonemura; T Sasaki
Journal:  Oral Oncol       Date:  1998-01       Impact factor: 5.337

10.  Impaired wound healing in mice with a disrupted plasminogen gene.

Authors:  J Romer; T H Bugge; C Pyke; L R Lund; M J Flick; J L Degen; K Dano
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440
View more
  12 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

Authors:  Theodore S Nowicki; Augustine L Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

Review 3.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

Review 4.  The mammalian molybdenum enzymes of mARC.

Authors:  Gudrun Ott; Antje Havemeyer; Bernd Clement
Journal:  J Biol Inorg Chem       Date:  2014-11-26       Impact factor: 3.358

Review 5.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

Review 6.  Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.

Authors:  Niaz Mahmood; Shafaat A Rabbani
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

7.  Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.

Authors:  V Heinemann; M P Ebert; R P Laubender; P Bevan; C Mala; S Boeck
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640

Review 8.  The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.

Authors:  Asmaa Anwar Ismail; Baraah Tariq Shaker; Khalid Bajou
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 9.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

Review 10.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

Authors:  Miguel Angel Pavón; Irene Arroyo-Solera; Maria Virtudes Céspedes; Isolda Casanova; Xavier León; Ramón Mangues
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.